EP1660885A1 - Reagens zur herstellung eines protein-chips - Google Patents

Reagens zur herstellung eines protein-chips

Info

Publication number
EP1660885A1
EP1660885A1 EP04771549A EP04771549A EP1660885A1 EP 1660885 A1 EP1660885 A1 EP 1660885A1 EP 04771549 A EP04771549 A EP 04771549A EP 04771549 A EP04771549 A EP 04771549A EP 1660885 A1 EP1660885 A1 EP 1660885A1
Authority
EP
European Patent Office
Prior art keywords
protein
cell
protein synthesis
freeze
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04771549A
Other languages
English (en)
French (fr)
Other versions
EP1660885A4 (de
EP1660885B1 (de
Inventor
Yaeta Endo
Tatsuya Sawasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFree Sciences Co Ltd
Original Assignee
CellFree Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellFree Sciences Co Ltd filed Critical CellFree Sciences Co Ltd
Publication of EP1660885A1 publication Critical patent/EP1660885A1/de
Publication of EP1660885A4 publication Critical patent/EP1660885A4/de
Application granted granted Critical
Publication of EP1660885B1 publication Critical patent/EP1660885B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof

Definitions

  • the present invention relates to a protein chip reagent using a cell-free protein synthesis system, to a kit for protein chip reagent using a cell-free protein synthesis system and to a test method using the reagent. More particularly, it relates to a reagent and a kit for a test and to a test method wherein a reagent manufactured by freeze-drying of a translation reaction solution where a substance necessary for protein synthesis, a translation template, a stabilizer, etc. are added to a solution containing a cell extract for a cell-free protein synthesis is used so as to express the protein upon each use and interaction with the said protein is utilized.
  • Such a solution containing cell extract for a cell-free protein synthesis and a protein synthesis reaction solution in which components necessary for translation except translation template and enzyme are added to the said extract-containing solution (hereinafter, that may be referred to as "a cell extract-containing solution of a ready-made type") are unstable at ambient temperature and have been able to be stably preserved only at an extremely low temperature of not higher than -80°C.
  • a cell-free protein synthesis system has a property which is as good as living cells in view of accuracy and speed of the translation reaction and is a useful method where a specific protein is able to be prepared without conducting complicated purifying steps.
  • Such a conventional method is a neck for constituting a fully automated system for the high throughput protein synthesis.
  • the present inventors have previously proposed a method for the manufacture of a preparation of a solution containing a cell extract for protein synthesis or a solution containing a cell extract of a ready-made type by means of freeze -drying (Patent Document 6).
  • Patent Document 6 a method for the manufacture of a preparation of a solution containing a cell extract for protein synthesis or a solution containing a cell extract of a ready-made type by means of freeze -drying.
  • Deterioration of quality means that, when water is added to the said preparation, the preparation is not completely dissolved and the synthetic activity in the protein synthesis reaction using the same is deteriorated as well.
  • An expression proteomics is a means for a full analysis of a specific protein in such a respect that in which place and to what extent it is expressed in a living body while a functional proteomics is a means for a full analysis of a specific protein in such a respect that with what molecule it conducts an interaction.
  • analyses have been carried out by means of a two-dimensional electrophoresis, a 2-hybrid method using yeast, a surface plasmon method, a phage display method, etc. but there are problems in terms of analytical time, sensitivity, pseudo-positivity reaction and quantity of date required for analysis and, accordingly, development for a protein chip where protein is accumulated in a high density has now been carried out.
  • ELISA method solid-phase enzyme immunoassay
  • MALDI-TOF MS matrix-assisted laser desorption ionization/time-of-flight mass spectrometer
  • Patent Document l Japanese Laid-Open Patent Publication Hei-6/98790
  • Patent Document 2- Japanese Laid-Open Patent Publication
  • Patent Document 3 Japanese Laid-Open Patent Publication Hei-7/194 Patent Document 4- Japanese Laid-Open Patent Publication Hei-9/291 Patent Document ⁇ - Japanese Laid-Open Patent Publication Hei-7/147992 Patent Document 6: Japanese Laid-Open Patent Publication 2000/316594 Patent Document 7- Japanese Laid-Open Patent Publication 2002/125693 Non-patent Document l: Koster, H., et al., Nature Biotechnol., 14,
  • An object of the present invention is to provide a protein chip reagent using a cell-free protein synthesis system by a simple operation which is particularly advantageous in a cell-free protein synthesis in many samples in a test using a specific protein or a high throughput analysis using the above-mentioned protein chip, etc. and also to provide a kit using the same. Further objects are to provide a kit for preparing a protein library or a protein chip using the above reagent and also to provide a test method for interacting substances.
  • the present inventors have repeatedly carried out intensive studies and, as a result, they have found that a specific protein is synthesized in a translation reaction solution of a microtiter plate when a translation reaction solution in which substances necessary for protein synthesis, translation template and stabilizer are added to a solution containing a cell extract for a cell-free protein synthesis is subjected to a dry-freezing in a well of a microtiter plate, calcium acetate is added to the said well to dissolve the reagent and then a translation reaction is carried out by layering a solution containing substrate, energy source, etc. used for the cell-free protein synthesis, energy source thereupon.
  • the present invention has been achieved on the basis of such a finding.
  • the present invention comprises the followings.
  • a protein chip reagent utilizing a cell-free protein synthesis system which comprises the following elements. &'• a solution containing cell extract for a cell-free protein synthesis comprising a wheat embryo extract wherefrom endosperm components and low-molecular protein synthesis inhibitors are substantially removed is added to each different well of a container which is partitioned in plural sections; b: at least the substances necessary for protein synthesis containing substrate and energy source and a specific translation template are added to the well mentioned in "a”> " and c: the solution in the well mentioned in "b” is freeze-dried preparation(by freeze -drying). 2.
  • a protein chip reagent utilizing a cell-free protein synthesis system which comprises the following elements.
  • ⁇ - a solution containing cell extract for a cell-free protein synthesis comprising a wheat embryo extract wherefrom endosperm components and low-molecular protein synthesis inhibitors are substantially removed is added to each different well of a container which is partitioned in plural sections
  • ' b at least the substances necessary for protein synthesis containing substrate and energy source and a specific translation template are added to the well mentioned in "a”
  • c' the solution in the well mentioned in "b” is freeze-dried preparation(by freeze-drying);
  • amount of a deliquescent substance in the freeze-dried preparation in the well mentioned in "c” is 0.01 part by weight or less to 1 part by weight of the protein in the said freeze-dried preparation.
  • a protein chip reagent utilizing a cell-free protein synthesis system which comprises the following elements.
  • a a solution containing cell extract for a cell-free protein synthesis comprising a wheat embryo extract wherefrom endosperm components and low-molecular protein synthesis inhibitors are substantially removed is added to each different well of a container which is partitioned in plural sections
  • ' b at least the substances necessary for protein synthesis containing substrate and energy source and a specific translation template are added to the well mentioned in "a”
  • ' c the solution in the well mentioned in "b” is freeze-dried preparationO y freeze-drying);
  • d" amount of a deliquescent substance in the freeze-dried preparation in the well mentioned in "c” is 0.01 part by weight or less to 1 part by weight of the protein in the said freeze-dried preparation;
  • e ' different kind type of translation template is contained in each the solution mentioned in "b” and makes two or more kinds of proteins synthesizable in each different well of the container
  • a protein chip reagent utilizing a cell-free protein synthesis system which comprises the following elements. a ⁇ a solution containing cell extract for a cell-free protein synthesis comprising a wheat embryo extract wherefrom endosperm components and low-molecular protein synthesis inhibitors are substantially removed is added to each different well of a container which is partitioned in plural sections, ' b ' at least the substances necessary for protein synthesis containing substrate and energy source and a specific translation template are added to the well mentioned in "a”; c ' the solution in the well mentioned in “b” is freeze-dried preparationOby freeze-drying), * d ' amount of a deliquescent substance in the freeze-dried preparation in the well mentioned in "c” is 0.01 part by weight or less to 1 part by weight of the protein in the said freeze-dried preparation,' e' different kind type of translation template is contained in each the solution mentioned in "b” and makes two or more kinds of proteins synthesizable in each different well of the container which is partitione
  • the modification for fixation is at least one which is selected from making into avidin, biotin, streptoavidin and His tag.
  • the kit for a cell-free protein synthesis containing the protein chip reagent utilizing a cell-free protein synthesis system mentioned in any of the above 1 to 5.
  • Fig. 1' It is a graph showing a synthesized amount of GFP protein where a regent of the present invention for a cell-free protein synthesis was used.
  • is a synthesized amount of GFP protein where the translation template was added and freeze-dried while
  • O is a synthesized amount of GFP protein where the translation reaction solution was not freeze-dried and the translation template was also added later.
  • Fig. 2 It is electrophoretic pictures showing protein contained in the translation reaction solution by an SDS-PAGE in a synthesis system using a reagent of the present invention for a cell-free protein synthesis.
  • Fig. 3 It is a radioautographic picture showing the protein contained in the translation reaction solution in a synthesis system using the reagent for a cell-free protein synthesis containing 96 kinds of different translation templates.
  • a wheat embryo extract having a protein synthesizing ability in a cell-free protein synthesis system is optimum.
  • a cell-free protein synthesis system means a method where components including ribosome which is a protein translation device being furnished in the cell are extracted from living body and then transcription or translation template, nucleic acid and amino acid to be used as a substrate, energy source, various ions, buffer and other effective factors are added followed by conducting in vitro.
  • cell-free translation system RNA is used as a template
  • cell-free transcription/translation system DNA is used and enzymes necessary for the transcription such as RNA polymerase are further added to conduct the reaction
  • cell-free transcription/translation system DNA is used and enzymes necessary for the transcription such as RNA polymerase are further added to conduct the reaction
  • the cell-free protein synthesis system of the present invention includes both of the above cell-free translation system and cell-free transcription/translation system.
  • specifically used ones are those prepared from microbes such as Escherichia coli, embryo of plant seeds and reticulocyte mammals such as rabbits, etc.
  • the solution containing a cell extract commercially available one may be used or it may be prepared from the above microbe, embryo, reticulocyte, etc. by a method known per se or, more particularly in that prepared from microbes such as Esclierichia coli, according to a method mentioned in Pratt, J. M., et al., Transcription and Translation, Hames, 179-209, B. D. & Higgins, S. J., eds., IRL Press, Oxford (1984).
  • Examples of the commercially available solution containing a cell extract are as follows. With regard to that derived from Escherichia coli, they are E.
  • a method for preparing a wheat embryo extract solution a method mentioned, for example, in Johnston, F. B., et al., Nature, 179, 160-161 (1957) is used as a method for isolation of wheat embryo while, as an extracting method for a solution containing a cell extract from isolated embryo, a method mentioned, for example, in Erickson, A. H., et al., (1996) Meth. in Enzymol., 96,38-50, etc. is used.
  • the endosperm containing the substances which suppresses the protein synthesis function (the substances such as tritin, thionine and ribonuclease which act on mRNA, tRNA, translation protein factor, ribosome, etc. and suppress their functions) contained or retained in the material cell per se is removed almost completely and purified.
  • the expression that the endosperm is removed almost completely and purified stands for an embryo extract wherefrom an endosperm part is removed to such an extent that ribosome is not substantially deadenylated while the expression that ribosome is not substantially deadenylated means that degree of deadenylation of ribosome is less than 7% or, preferably, 1% or less.
  • the above-mentioned embryo extract contains proteins which are derived from the solution containing the cell extract or are separately added upon necessity.
  • the adding amount thereof is preferably 1 to 10% by weight or, more preferably, 2.5 to 5% by weight to the total composition in the case of a composition before the freeze-drying in view of stability upon preservation under the freeze-dried state or of usability and, in the case of a freeze-dried composition after the freeze-drying, it is preferably 10 to 90% by weight or, more preferably, 25 to 70% by weight of the total freeze-dried composition.
  • the protein content used here is that which is calculated by measuring the absorptions (260, 280 and 320 nm).
  • concentration of the deliquescent substances contained in the said cell extract-containing solution is decreased within such an extent that quality of the preparation is not affected.
  • Specific method for decreasing the deliquescent substances includes a gel filtration using a gel carrier which is previously equilibrated with a solution containing a decreased amount of or no deliquescent substances, a dialysis method, etc. By the method as such, a decrease is conducted to such an extent that the final concentration of the deliquescent substances in the finally prepared translation reaction solution is made not more than 60 mM.
  • concentration of potassium acetate contained in the finally prepared translation reaction solution is decreased to not more than 60 mM or, preferably, not more than 50 mM.
  • the amount of the substance showing deliquescence (deliquescent substance) which does not deteriorate the preservation stability under the freeze-dried state in the freeze-dried preparation is preferably not more than 0.01 part by weight or, particularly preferably, not more than 0.005 part by weight to 1 part by weight of protein contained in the said freeze-dried preparation. Decreasing of the deliquescent substance may be carried out after preparing the solution containing the cell extract or may be carried out in any of the steps until preparation of the solution containing the cell extract.
  • the solution containing a cell extract may contaminate microbes, particularly spores of fungi and it is preferred to remove such microbes. Growth of the microbe may be sometimes noted particularly in a cell-free protein synthesis reaction for a long period (one day or longer) and, therefore, it is important to inhibit that.
  • a filtration sterilization filter there is no particular limitation for the means of removing the microbes, it is preferred to use a filtration sterilization filter.
  • the pore size of the filter there is no particular limitation so far as it is a size by which microbes having a possibility of contamination are able to be removed and, usually, it is 0.1 to 1 micrometer or, preferably, 0.2 to 0.5 micrometer.
  • low-molecular synthesis inhibitors are fractionated and removed by means of difference in molecular weights from the constituting components of the solution containing a cell extract.
  • the low-molecular synthesis inhibitors are able to be fractionated as molecules having molecular weights of not more than the smallest one among the factors necessary for synthesis of protein contained in the solution containing a cell extract.
  • they are able to be fractionated and removed as those having molecular weights of not more than 50,000 to 14,000 and, preferably, not more than 14,000.
  • a method for removal of low-molecular synthesis inhibitors from a solution containing a cell extract a commonly used method which has been known per se is used and, to be specific, a method by dialysis by way of a permeable membrane, a gel filtration method and an ultrafiltration method may be exemplified.
  • a method by dialysis is preferred in view of easiness in providing a substance to an inner liquid for the dialysis.
  • a permeable membrane used for a removing operation of the lowmolecular synthesis inhibitors by means of dialysis that having a removing molecular weight of 50,000 to 12,000 is exemplified.
  • a regenerated cellulose membrane having a removing molecular weight of 12,000 to 14,000 (manufactured by Viskase Sales, Chicago), a Spectra/Pore 6 having a removing molecular weight of 50,000 (manufactured by Spectrum Laboratories Inc., CA, U. S. A.), etc. are preferably used.
  • An appropriate amount of a solution containing a cell extract or the like is placed in such a permeable membrane and dialysis is carried out by a conventional method. With regard to the time for the dialysis, about 30 minutes to 24 hours is preferred.
  • stabilization of a solution containing a cell extract When insoluble components are produced in the solution containing a cell extract in conducting the removal of the low-molecular synthesis inhibitors, the production as such is inhibited (hereinafter, that may be referred to as "stabilization of a solution containing a cell extract") whereby it is possible to enhance the protein synthesis activity of the finally-prepared cell extract-containing solution or translation reaction solution.
  • An example of the specific method for stabilization of the cell extract-containing solution or translation reaction solution is that, in conducting the removal of the above-mentioned low-molecular synthesis inhibitors, the cell extract-containing solution or translation reaction solution is made as a solution containing at least a high-energy phosphoric acid compound such as ATP or GTP (hereinafter, that may be referred to as "stabilizing component").
  • ATP is preferably used as a high-energy phosphoric acid compound.
  • that is preferably carried out in a solution containing ATP and GTP or, more preferably, ATP, GTP and 20 kinds of amino acids.
  • Those components may be subjected to a removing step for the low-molecular inhibitors after adding the stabilizing components thereto followed by incubating previously or, when a dialysis method is used for the removal of the low-molecular synthesis inhibitors, it is also possible that the stabilizing components are also added to the outer solution for dialysis followed by dialyzing whereupon the lowmolecular synthesis inhibitors are removed.
  • the stabilizing components are also added to the outer liquid for the dialysis, new stabilizers are always supplied even when the stabilizers are decomposed during the dialysis and, therefore, that is more preferred. That is also applicable to the case where a gel filtration method or an ultrafiltration method is used and the similar effect is able to be achieved when each carrier is equilibrated with a buffer for filtration containing stabilizing components, then the cell extract-containing solution or translation reaction solution containing the stabilizing components is supplied and the filtration is carried out together with addition of the above buffer. Adding amount of the stabilizing components and time for the stabilizing treatment may be appropriately selected depending upon the type and preparing method of the cell extract-containing solution.
  • An example of the method for the selection is that stabilizing components which were assigned with quantity and type on a test basis are added to a cell extract-containing solution, low-molecular inhibitors are removed after an appropriate period, the resulting cell extract- containing solution after the treatment is separated into soluble and insoluble components by means of centrifugal separation or the like and the product containing less insoluble components is selected.
  • Another preferred method is that a cell-free protein synthesis is carried out using the resulting cell extract-containing solution after the treatment and the product containing (showing) higher protein synthesis activity is selected.
  • Another method is that, when a cell extract-containing solution and a dialysis method are used in the above-mentioned selection method, appropriate stabilizing components are also added to the outer liquid for the dialysis, dialysis is carried for an appropriate period using that and the selection is conducted depending upon the amount of the insoluble components in the resulting cell extract-containing solution or upon the protein synthesis activity, etc. of the resulting cell extract-containing solution.
  • a specific condition for the stabilization of the cell extract-containing solution selected as such is that, in case the removal step of lowmolecular synthesis inhibitors is conducted by a dialysis method, 100 ⁇ M to 0.5 mM of ATP, 25 ⁇ M to 1 mM of GTP and each 25 ⁇ M to 5 mM of 20 kinds of amino acids are added to the wheat embryo extract-containing solution and the outer liquid for the dialysis and dialysis is carried out for 30 minutes to more than 1 hour.
  • the temperature in case dialysis is carried out any temperature may be adopted so far as the protein synthesis activity of the cell extract-containing solution is not lost and the dialysis is possible.
  • the lowest temperature is the temperature where the solution is not frozen and is usually -10°C or, preferably, -5°C while the highest temperature is 40°C or, preferably, 38°C which is the limit of the temperature whereby the solution used for the dialysis is not badly affected.
  • the above stabilizing components are further added to the cell extract- containing solution.
  • the reducing agent in terms of the concentration in the finally-prepared cell extract-containing solution is decreased to such a concentration that protein is able to be synthesized in the translation reaction using the said cell extract-containing solution and the intramolecular disulfide bond is able to be formed and retained.
  • DTT dithiothreitol
  • its final concentration in the final translation reaction solution prepared from the cell extract-containing solution is decreased to a range of 20 to 70 ⁇ M or, preferably, 30 to 50 ⁇ M.
  • the final concentration in the translation reaction solution is decreased to a range of 0.1 to 0.2 mM.
  • Concentration of the above-mentioned specific reducing agent is not limited thereto but may be appropriately changed depending upon the type of the protein to be synthesized and upon the type of the cell-free protein synthesis system used.
  • a method for selecting the optimum concentration range of a reducing agent there is no particular limitation and, for example, a method where judgment is done by the effect of the enzyme which catalyzes a disulfide bond exchange reaction may be exemplified.
  • translation reaction solutions derived from a cell extract-containing solution to which concentrations of the reducing agent are assigned are prepared and then an enzyme which catalyzes a disulfide bond exchange reaction is added to conduct a synthesis of protein having a disulfide bond in a molecule.
  • an enzyme which catalyzes a disulfide bond exchange reaction is added to the translation reaction solution which is the same as above.
  • Soluble components of protein synthesized here are separated by, for example, means of a centrifugal separation.
  • a reaction solution in which the soluble components are not less than 50% (solubilizing rate' 50%) of the whole and the soluble components increase as a result of addition of the enzyme catalyzing the disulfide bond exchange reaction is able to be judged to be suitable as a reaction solution which synthesizes the protein wherein the intramolecular disulfide bond is retained. Further, among the concentration range of the reducing agent selected by the effect of the enzyme catalyzing the above disulfide bond exchange reaction, the concentration of the reducing agent where the amount of the synthesized protein is biggest is able to be selected as the more preferred concentration range.
  • a specific method for decreasing the reducing agent there may be used a method where a cell extract-containing solution containing no reducing agent is prepared and a reducing agent is added together with components necessary for a cell-free protein synthesis system thereto so as to give the above-mentioned concentration range, a method where a reducing agent is removed from a translation reaction solution derived from a cell extract-containing solution so as to give the above-mentioned concentration range, etc.
  • a reducing condition of a high degree is necessary for a cell extract-containing solution for a cell-free protein synthesis in conducting the extraction and, therefore, a method where a reducing agent is removed from the solution after extraction is easier.
  • a method for removing the reducing agent from a cell extract-containing solution a method where a carrier for gel filtration is used, etc. may be exemplified.
  • a method where Sephadex G-25 column is previously equilibrated with an appropriate buffer containing no reducing agent and then a cell extract-containing solution is passed therethrough, etc. may be exemplified.
  • (5) Preparation of a translation reaction solution To the cell extract-containing solution which is prepared as such are added nuclease inhibitor, various ions, substrate, energy source, etc.
  • additives to the translation reaction solution mRNA encoding a specific protein which is to be a translation template and a stabilizer containing at least one component selected from a group consisting of inositol, trehalose, mannitol and sucrose-epichlorohydrin copolymer whereupon a translation reaction solution is prepared. Adding concentration of each component is able to be achieved by a compounding ratio which has been known per se.
  • the additives to the translation reaction solution are amino acid to be used as a substrate, energy sources, various ions, buffer, ATP regenerating system, nuclease inhibitor, tRNA, reducing agent, polyethylene glycol, 3',5'-cAMP, ate and antibacterial agent.
  • concentrations it is preferred to add in such a manner that ATP, GTP and each of 20 kinds of amino acids are made contained in amount ranges of 100 ⁇ M to 0.5 mM, 25 ⁇ M to 1 mM and 25 ⁇ M to 5 mM, respectively. They may be used after appropriately selected and combined depending upon the translation reaction system.
  • a wheat embryo extract solution is used as a cell extract-containing solution
  • an example is that 20 mM of HEPES-KOH (pH: 7.6), 100 mM of potassium acetate, 2.65 mM of magnesium acetate, 0.380 mM of spermidine (manufactured by Nakarai Tesk), each 0.3 mM of 20 kinds of L-amino acids, 4 mM of dithiothreitol, 1.2 mM of ATP (manufactured by Wako Pure Chemical), 0.25 mM of GTP (manufactured by Wako Pure Chemical), 16 mM of creatinephosphoric acid (manufactured by Wako Pure Chemical), 1 U/ ⁇ l of RNase inhibitor (manufactured by Takara) and 0.5 ⁇ g/1 of creatine kinase (manufactured by Roche) are added and, after they are well dissolved, 1 ⁇ g of a translation template mRNA ( ⁇ G)
  • RNA polymerase any encoding protein which is able to be synthesized in a cell-free protein synthesis system is linked at a downstream area of a sequence recognizing an appropriate RNA polymerase and a sequence having a function of activating the translation.
  • An example of the sequence which is recognized by an RNA polymerase is a T3 or T7 RNA polymerase promoter.
  • a reagent for the cell-free protein synthesis of the present invention may be appropriately selected depending upon each object.
  • a sequence which enhances the translation activity in a cell-free protein synthesis system that having a structure where ⁇ sequence or the like is linked to a 5'-upstream side of the coding sequence is preferably used.
  • (6) Method for freeze-drying With regard to a freeze-drying, a cell extract-containing solution, a specific translation template and appropriately selected additives for the translation reaction solution are mixed and a freeze-drying treatment is carried out.
  • Combinations of the embodiment as such are as follows.
  • Type 1 ' Cell extract-containing solution, specific translation template and additives for translation reaction solution are uniformly mixed and made into a freeze-dried preparation.
  • Type 2 ' Cell extract-containing solution, specific translation template and additives for translation reaction solution are uniformly mixed and made into a freeze-dried preparation and additives for translation reaction solution are made into a kit while the additives for translation reaction solution are added to the upper layer of the cell upon the protein synthesis reaction.
  • Type 3 ' Cell extract-containing solution and specific translation template together with additives for translation reaction solution are layered as the lower layer and the upper layer of the cell, respectively and then they are made into a freeze-dried preparation.
  • Type 4' In addition to the Type 3, additives for translation reaction solution are further made into a kit and, during the protein synthesis reaction, the additives for translation reaction solution are added to the upper layer.
  • Type 5" Cell extract-containing solution and specific translation template are mixed and made into a freeze-dried preparation while additives for translation reaction solution are made into a kit and the additives for translation reaction solution are added to the upper layer.
  • a method for the freeze-drying may be appropriately selected from commonly-used methods which have been known per se and, to be specific, it may be carried out in such a manner that, for example, a quick freezing is conducted by liquid nitrogen, reduced pressure is resulted by means of a vacuum pump for example and, after that, temperature of a container is gradually raised.
  • a commercially available freeze-drier is used. It is preferred that temperature, time, etc. for the freeze-drying are in accordance with the directions for use of the freeze-drier used therefor.
  • the freeze-dried preparation of the present invention which is prepared by completion of dehydration as such is very stable at room temperature and, in addition, a cell extract-containing solution prepared by addition of water or the like thereto has a protein synthesis activity which is favorably comparable with the case of being preserved at an extremely low temperature. Substitution of the air in the container for preservation with nitrogen gas is more preferred as a method for preservation of the said preparation. It is preferred in the present invention that concentration of the cell extract-containing solution during the preparation before freeze-drying is adjusted to 0.1 to 100 mg/ml or, more preferably, 1 to 50 mg/ml. In conducting a freeze-drying, a sample to be charged is placed in a freeze-drier and allowed to stand.
  • the inner temperature of the freeze-drier is cooled down to -30°C or lower to freeze the sample charged therein.
  • inner area of the freeze-drier is made in vacuo and temperature is raised to such an extent that the charged sample is not melted so as to sublime the water whereupon a primary freeze-drying is carried out.
  • temperature of inner area of the freeze-drier is raised so as to remove the attached water whereupon a secondary drying is carried out.
  • the container is partitioned in plural sections and there is no particular limitation so far as the above-mentioned translation reaction solutions in the sections as such are not mixed each other.
  • the numbers of the sections a range of 10 to 200 will be acceptable and particularly preferred ones are those as stipulated by the standards such as 48, 96, 384 and 1536 sections.
  • the material of the container and a commercially available microtiter plate or the like is preferably used.
  • the position (coordinate) of the well is made correspondent to the translation template.
  • a' A cell extract-containing solution for a cell-free protein synthesis suitable for the volume of the well is added to each of different wells in the container partitioned in plural sections using a pipetteman or the like and/or a channel pipetter of the automatic dispenser.
  • b ' A solution containing necessary amount of a solution containing substances necessary for protein synthesis, translation template and stabilizer is added to each well mentioned in "a” using a pipetteman or the like and/or a channel pipetter of the automatic dispenser.
  • c' The solution in the well prepared in "b” is made into a freeze-dried preparation using the above freeze-drying method. If necessary, it is also possible to use a component which was already subjected to the following treatment.
  • a component where a deliquescent substance in the freeze-dried preparation is decreased.
  • a lowmolecular protein synthesis inhibitor is removed and/or concentration of a reducing agent is decreased.
  • (8) Method for the synthesis of protein using a protein chip reagent utilizing a cell-free protein synthesis system The above-prepared protein chip reagent utilizing a cell-free protein synthesis system is dissolved in a dissolving solution where the above-decreased deliquescent substance and water are added so as to give a concentration suitable for the protein synthesis reaction and then poured into each selected system or device which is known per se whereupon protein synthesis is able to be carried out. Examples of the system or device for the protein synthesis are as follows.
  • a protein disulfide isomerase when added to a translation reaction solution containing 20 to 70 or, preferably, 30 to 50 ⁇ M of DTT as a reducing agent, it is added within such an extent that its final concentration in the translation reaction solution is made within a range of 0.01 to 10 ⁇ M or, preferably, 0.5 ⁇ M. With regard to the stage for the addition, it is preferred to add prior to the start of the translation reaction in view of efficiency for the formation of a disulfide bond.
  • the protein library which is prepared using a reagent for a protein library according to the present invention may be used, for example, as a protein chip. Especially when a mechanized protein chip production is carried out, it is preferred to use a microtiter plate meeting the standards for a protein chip manufacturing device as a container for a kit of the present invention.
  • Embodiments of protein chip reagent A translation template contained in the translation reaction solution has a structure of adding a modification for fixation to protein encoded thereby and two or more translation reaction solutions each containing different translation template are freeze-dried in a container partitioned into plural sections and in each different well where a substance having an affinity to the substance which is added as a result of the above-mentioned modification for fixation is coated on bottom of the well and/or carrier in the well whereupon a protein chip reagent is prepared.
  • protein chip it means a chip where two more kinds of protein are separately fixed on an appropriate base (surface of a well) or a chip which is present in a well.
  • the protein chip is used for analysis (hereinafter, it may be referred to as "proteome analysis") of bonding property or interacting property of protein with protein, nucleic acid, lowmolecular compound or sugar chain, etc.
  • proteome analysis a buffer having a concentration suitable for a cell-free protein synthesis reaction
  • a buffer having a concentration suitable for a cell-free protein synthesis reaction is added to the protein chip reagent according to the present invention so that the reagent is dissolved therein and kept at an appropriate temperature
  • proteins are able to be synthesized at the same time and, since the synthesized proteins are bonded to the bottom of the well or are present in the well, it is possible to prepare a protein chip.
  • a method for the translation reaction is the same as that mentioned hereinabove already.
  • Test method for the interacting substances is able to be carried out by including at least the following steps. a- a freeze-dried reagent for a cell-free protein synthesis is dissolved upon each use; and b' after dissolving the reagent for a cell-free protein synthesis, conditions for translation reaction of protein are adjusted, synthesis of specific protein is carried out by the above-mentioned method and the said protein is expressed in a well. If necessary or depending upon the type of the sample, the following steps are added.
  • a substance which interacts with the specific protein is judged from the sample either qualitatively or quantitatively.
  • protein chip reagent and a test method for the interacting substance with a specific protein protein which is synthesized by a cell-free protein synthesis system if desired is modified for fixation and, further, it is possible to use a well and/or a carrier which is coated with a substance having an affinity for a substance added by a modification for the said fixation to a carrier on the surface of a well and/or in a well.
  • Examples of a combination of a modification for fixation with a substance having affinity for a substance being added by modification for fixation are protein bonded to biotin such as avidin or streptoavidin/biotin, protein bonded to maltose/maltose, G protein/guanine nucleotide, polyhistidine peptide/metal such as nickel or cobalt, glutathione-S-transferase/glutathione, protein bonded to DNA DNA, antibody/antigen molecule (epitope), calmodulin/peptide bonded to calmodulin, protein bonded to ATP/ATP or estradiol receptor protein/estradiol and other various receptor protein/ligand thereof.
  • biotin such as avidin or streptoavidin/biotin
  • protein bonded to maltose/maltose G protein/guanine nucleotide
  • polyhistidine peptide/metal such as nickel or cobalt
  • beads, Sephadex resin, etc. may be exemplified although there is no particular limitation provided that the synthetic protein is able to be bonded to the surface of a carrier.
  • a method for modification for fixation to protein encoded by translation template any method will be acceptable so far as it is a method where modification for fixation is possible to protein which is synthesized in a cell-free protein synthesis system.
  • a method where synthesis of protein is carried out using a translation reaction solution in which tRNA bonded to a substance to be added by means of modification for fixation (hereinafter, that may be referred to as "substance for fixation") is added; a method where synthesis of protein is carried out using a product where a sequence encoding a substance for fixation is added to a translation template in case polypeptide is used as the substance; a method where a substance for fixation is directly added to C terminal of protein by a nucleic acid derivative such as puromycin in a protein synthesis system (Japanese Laid-Open Patent No. 11/322,781); etc.
  • a spacer having a suitable length between a substance for fixation and mRNA encoding protein.
  • a macromolecular substance such as polyethylene and polyethylene glycol may be used and, preferably, polyethylene glycol is used.
  • a method for bonding a substance which specifically bonds to a substance for fixation
  • a method which has been known per se may be used and, to be specific, a method using, for example, tannic acid, formalin, glutaraldehyde, pyruvic aldehyde, bis-diazotized benzisone, toluene-2,4-diisocyanate, amino group, carboxyl group or hydroxyl group or amino group, etc.
  • a container used the above-mentioned one may be used and that may be appropriately selected depending upon a method for the detection used in proteome analysis.
  • a translation template contained in a translation reaction solution may be appropriately selected depending upon the purpose of the proteome analysis using a protein chip prepared by the protein chip synthesis kit of the present invention.
  • mRNA having a sequence encoding a functional protein is selected.
  • ion channel transporter, growth factor, hydrolase, synthase, oxidation-reduction enzyme, proteinous inhibitor, physiologically active peptide, peptidergic toxin, receptor such as that of a G protein conjugation type, ligand and antibody.
  • a sample to be measured although there is no particular limitation so far as it is a substance which interacts with specific protein and/or translation template for the said specific protein, its examples are protein, nucleic acid, lowmolecular compound and sugar chain.
  • a cell-free protein synthesis reagent containing what translation template is placed in which well of a container although it is preferred that the position (coordinate) of a well corresponds to the translation template.
  • a method for the freeze-drying is the same as that mentioned above already.
  • a method for a qualitative or quantitative determination of a substance which interacts with a specific protein there is no particular limitation so far as it is a method being able to detect an interaction of the sample with the specific protein.
  • ELISA enzyme-linked immunosorbent assay
  • a microtiter plate made of plastic which is usually used in ELISA is preferred.
  • a surface plasmon resonance method Cullen, D.
  • a substrate is labeled, a specific protein synthesized by a cell-free protein synthesis system is labeled and the interacting substance is traced either qualitatively or quantitatively using the said label as a marker.
  • a labeling means at that time, common means such as heavy hydrogen, radioisotope, fluorescent substance and chromogen substance may be exemplified.
  • Example 1 Protein synthesis using a freeze-dried reagent of a translation reaction solution containing a translation template (l) Preparation of a wheat embryo extract Seeds of wheat (non-disinfected) of chihoku variety produced in
  • Pulverisette 14 Type manufactured by Fritsch Pulverisette 14 Type manufactured by Fritsch
  • the color selector is a device equipped with a means for irradiating the light to the crude embryo fraction, a means for detecting the reflected light and/or transmitted light from the crude embryo fraction, a means for comparing the detected value with the standard value and a means for the selection and removal of the thing which is out of or within the standard value.
  • the crude embryo fraction was supplied onto a beige belt of the color selector at the rate of 1,000 to 5,000 grains/cm 2 , light from a fluorescent lamp is irradiated to the crude embryo fraction on the belt and the reflected light was detected. Conveying speed of the belt was made 50 m/minute.
  • a monochrome CCD line sensor (2048 pixels) was used as a light-receiving sensor. Firstly, in order to remove black components (seed coat, etc.) from the embryo, a standard value was set up between luminance of the embryo and luminance of the seed coat and those which were out of the standard value were removed by suction.
  • a standard value was set up between luminance of the embryo and luminance of the endosperm and those which were out of the standard value were removed by suction.
  • the suction was carried out using 30 suction nozzles (one suction nozzle for each cm of the length) which were placed at the positions of about 1 cm above the conveying belt.
  • the embryo was selected until purity of the embryo (rate by weight of the embryo contained in 1 g of a sample) became 98% or more.
  • the resulting wheat embryo fraction was suspended in distilled water of 4°C and washed using an ultrasonic cleaner until the washing was no longer turbid.
  • Nonidet P40 manufactured by Nakarai Tesk
  • a supernatant liquid prepared by centrifugal separation of the above-prepared homogenate at 30,000 x g for 30 minutes using a high-speed centrifugal separator was subjected to a centrifugal separation once again under the same condition and the supernatant liquid was prepared.
  • the resulting sample did not show deterioration of activity upon a long-term preservation at not higher than -80°C.
  • the resulting supernatant liquid was passed through a filter having a pore size of 0.2 ⁇ m (New Stella Disk 25, manufactured by Kurabo) whereupon sterilization by filtration and removal of contaminated fine dusts were conducted. After that, the filtrate was subjected to gel filtration using a column of
  • ⁇ GFP translation template mRNA
  • SP6 RNA polymerase manufactured by Toyobo
  • TMV tobacco mosaic virus
  • a pladmid GFP/pEU containing GFP gene DNA connected to 3'-downstream WO 01/27260
  • the mRNA (l ⁇ g) was added to the translation reaction solution material manufactured in Example 1 to prepare a translation reaction solution.
  • (3) Freeze-dried preparation The above-mentioned translation reaction solution to which the translation template was added was dialyzed against an outer liquid for dialysis to give a translation reaction solution of a type where a deliquescent substance was decreased (concentration of potassium acetate was 0 to 50 mM). After the dialysis, each translation reaction solution was frozen with liquid nitrogen and dehydrated by an operation for 3 hours using a freezer-drier (Freeze Dry System Freezone 4.5; manufactured by Labconco) in accordance with the direction for use attached thereto.
  • a freezer-drier Freeze Dry System Freezone 4.5; manufactured by Labconco
  • a powdery sample prepared as such was tightly sealed being filled with nitrogen so that the components were not chemically changed and preserved at 4°C.
  • (4) Translation reaction and analysis of amount of the synthesized protein The reagent for a cell-free protein synthesis which was made into a freeze-dried preparation as above was dissolved in 40-50 ⁇ l of a 100 mM magnesium solution. As a control, a preparation where 1 ⁇ g of the translation template mRNA mentioned in the above-mentioned step (3) was added to a translation reaction solution material liquid prepared in the above-mentioned step (l) was prepared.
  • Those translation reaction solutions were subjected to a dialysis system using an outer liquid for dialysis (20 mM of HEPES-KOH, pH 7.6, 100 mM of potassium acetate, 2.65 mM of magnesium acetate, 4 mM of dithiothreitol, 1.2 mM of ATP, 0.25 mM of GTP, 16 mM of creatine phosphate, 0.5 mg/ml of creatine kinase, 0.380 mM of spermidine, 20 kinds of L-amino acids (each 0.3 mM) and 0.005% of NaN ⁇ ) in an amount of 10-fold by volume of the reaction solution and protein synthesis reaction was carried out at 26°C for 48 hours.
  • an outer liquid for dialysis (20 mM of HEPES-KOH, pH 7.6, 100 mM of potassium acetate, 2.65 mM of magnesium acetate, 4 mM of dithiothreitol, 1.2 mM of ATP, 0.25
  • FIG. 2B show the reaction products of a synthesis system where the translation reaction solution to which the translation template was added was freeze-dried.
  • the translation reaction solution which was freeze-dried in a state where the translation template was added showed the same protein synthesis activity as in the case where the translation reaction solution which was not freeze-dried was used.
  • Example 2 Simultaneous synthesis of polyclonal protein
  • Each 30 ⁇ g of 96 kinds of translation template mRNA were added to the translation reaction solution prepared by the same manner as in Example 1 and each 50 ⁇ l thereof were placed in each well of a 96-well microtiter plate. That was freeze-dried and preserved by the same manner as in Example 1.
  • Each 40 to 50 ⁇ l of a 100 mM potassium acetate solution were placed to and dissolved in each well containing the resulting reagent for a cell-free protein synthesis. After that, to each solution were added 4 ⁇ Ci of 14 C-leucine (100 mCi/mmol) per ml of the translation reaction solution.
  • a solution comprising 30 mM of Hepes-KOH (pH 7.6), 95 mM of potassium acetate, 2.65 mM of magnesium acetate, 2.85 mM of dithiothreitol, 1.2 mM of ATP, 0.25 mM of GTP, 16 mM of creatine phosphate, 0.380 mM of spermidine and 20 kinds of L-amino acids (0.3 mM) as a solution for supplying of substrate and energy (hereinafter, that will be referred to as "supplying solution”) containing amino acids, energy source and other ions, etc. necessary for the reaction was layered on the upper layer of the solution without disturbing the interface.
  • supplying solution containing amino acids, energy source and other ions, etc. necessary for the reaction was layered on the upper layer of the solution without disturbing the interface.
  • kits for preparing a protein library containing a synthetic reagent containing freeze-dried different translation templates in each well of a microtiter plate and there is also provided a kit for preparing a protein chip where a structure of binding to the bottom of a synthetic container is given to the synthesized protein.
  • the present invention is particularly useful for a high throughput analysis such as function of protein handling many clones or for a test using a specific protein.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP04771549A 2003-08-07 2004-08-05 Reagens zur herstellung eines protein-chips Not-in-force EP1660885B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003288859 2003-08-07
US54220104P 2004-02-05 2004-02-05
PCT/JP2004/011567 WO2005015212A1 (en) 2003-08-07 2004-08-05 Reagent for producing a protein chip

Publications (3)

Publication Number Publication Date
EP1660885A1 true EP1660885A1 (de) 2006-05-31
EP1660885A4 EP1660885A4 (de) 2007-05-30
EP1660885B1 EP1660885B1 (de) 2012-10-03

Family

ID=34137924

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04771549A Not-in-force EP1660885B1 (de) 2003-08-07 2004-08-05 Reagens zur herstellung eines protein-chips

Country Status (3)

Country Link
EP (1) EP1660885B1 (de)
JP (1) JP2007528718A (de)
WO (1) WO2005015212A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010256010A (ja) * 2006-11-02 2010-11-11 Olympus Corp 蛍光分析による抗原抗体反応検出方法
JP2011209224A (ja) * 2010-03-30 2011-10-20 Fujita Gakuen 抗原検索法及び抗体検出法
JP6521255B2 (ja) * 2013-08-30 2019-05-29 国立大学法人 東京大学 タンパク質アレイ又はペプチドアレイの製造方法、機能性タンパク質又は機能性ペプチドの同定方法、タンパク質アレイ又はペプチドアレイ、及び、機能性タンパク質又は機能性ペプチド同定キット
CN114891855A (zh) 2013-12-06 2022-08-12 哈佛大学校长及研究员协会 基于纸的合成基因网络

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176210A1 (de) * 1999-05-11 2002-01-30 Wakenyaku Co., Ltd. Zubereitung, die einen zellextrakt zur herstellung eines zellfreien proteins enthalten und vorrichtung zur herstellung eines zellfreien proteins
WO2002014860A1 (en) * 2000-08-15 2002-02-21 Discerna Limited Functional protein arrays
EP1314781A1 (de) * 2000-08-30 2003-05-28 Endo, Yaeta, Dr. DESIGN UND KONSTRUKTION EINER TRANSKRIPTIONSSCHABLONE FüR DIE SYNTHESE VON ZELLFREIEM PROTEIN UND CHARGENARTIGES VERDüNNUNGSVERFAHREN ZUR SYNTHESE VON ZELLFREIEM WEIZENKEIMPROTEIN DURCH VERWENDUNG DESSELBEN
US20030199076A1 (en) * 2000-10-19 2003-10-23 Toyo Boseki Kabushiki Kaisha Composition for cell-free protein synthesis
EP1541588A1 (de) * 2002-07-18 2005-06-15 CellFree Sciences Co., Ltd. Einzelkettenantikörper und dessen anwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06225783A (ja) * 1992-12-07 1994-08-16 Nippon Flour Mills Co Ltd 無細胞タンパク合成系を用いたタンパクの製造方法
AU771248B2 (en) * 1999-01-22 2004-03-18 Martek Biosciences Corporation Simple method for labeled conjugate production
JP2000316594A (ja) * 1999-05-11 2000-11-21 Wakenyaku Kk 無細胞タンパク質合成用細胞抽出物含有製剤、及び無細胞タンパク質合成反応用キット
IL150291A0 (en) * 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176210A1 (de) * 1999-05-11 2002-01-30 Wakenyaku Co., Ltd. Zubereitung, die einen zellextrakt zur herstellung eines zellfreien proteins enthalten und vorrichtung zur herstellung eines zellfreien proteins
WO2002014860A1 (en) * 2000-08-15 2002-02-21 Discerna Limited Functional protein arrays
EP1314781A1 (de) * 2000-08-30 2003-05-28 Endo, Yaeta, Dr. DESIGN UND KONSTRUKTION EINER TRANSKRIPTIONSSCHABLONE FüR DIE SYNTHESE VON ZELLFREIEM PROTEIN UND CHARGENARTIGES VERDüNNUNGSVERFAHREN ZUR SYNTHESE VON ZELLFREIEM WEIZENKEIMPROTEIN DURCH VERWENDUNG DESSELBEN
US20030199076A1 (en) * 2000-10-19 2003-10-23 Toyo Boseki Kabushiki Kaisha Composition for cell-free protein synthesis
EP1541588A1 (de) * 2002-07-18 2005-06-15 CellFree Sciences Co., Ltd. Einzelkettenantikörper und dessen anwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005015212A1 *

Also Published As

Publication number Publication date
WO2005015212A1 (en) 2005-02-17
JP2007528718A (ja) 2007-10-18
EP1660885A4 (de) 2007-05-30
EP1660885B1 (de) 2012-10-03

Similar Documents

Publication Publication Date Title
US10451631B2 (en) Microarray compositions and methods of their use
Espina et al. Protein microarray detection strategies: focus on direct detection technologies
CA2419490C (en) Functional protein arrays
Weinrich et al. Applications of protein biochips in biomedical and biotechnological research
Hu et al. Functional protein microarray technology
US7364911B2 (en) Methods for isolating and labeling sample molecules
Zhu et al. Applications of functional protein microarrays in basic and clinical research
Merkel et al. Functional protein microarrays: just how functional are they?
US11639938B2 (en) Multiplexed bead-based analytical assays
US7150978B2 (en) Recombinant template used for producing a carboxy-terminal modified protien and a method of producing a carboxy-terminal modified protein
US20070105152A1 (en) Methods for determining protein binding specificity using peptide libraries
Lande et al. Dissecting the chloroplast proteome of chickpea (Cicer arietinum L.) provides new insights into classical and non-classical functions
EP2045332B1 (de) Proteomweite Quantifizierung kleiner an zelluläre Zielproteine gebundener Moleküle
EP1660885B1 (de) Reagens zur herstellung eines protein-chips
WO2007124143A2 (en) Methods for high-throughput screening of cell lines
CN108841828B (zh) 一种特异性识别妥布霉素的单链dna适配体及其应用
US20060188947A1 (en) Reagent for producing a protein chip
US7674593B2 (en) Preparation method of biotinylated protein and detection method using the same
Fasolo et al. Protein microarrays
Feilner et al. Proteomic studies using microarrays
Predki Functional protein microarrays in drug discovery
JP2005098830A (ja) 質量分析法によるタンパク質相互作用物質のスクリーニング方法
EP1916521A1 (de) Verfahren für die analyse der bindenden eigenschaft eines proteins für verbindungen
Speicher Overview of proteome analysis
US20230236170A1 (en) Reactive affinity probe-interaction discovery platform

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070504

17Q First examination report despatched

Effective date: 20070604

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 578189

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121015

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004039562

Country of ref document: DE

Effective date: 20121206

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 578189

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20121003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130204

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130104

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130103

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

26N No opposition filed

Effective date: 20130704

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004039562

Country of ref document: DE

Effective date: 20130704

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140301

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004039562

Country of ref document: DE

Effective date: 20140301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130805

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040805

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150819

Year of fee payment: 12

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160805